Advanced search

Graham Shuttleworth is currently a Director at Positive Steps Oldham Ltd.
He previously worked as a Trustee at Greater Manchester Sports Partnership.

Graham Patrick Shuttleworth is Chief Financial Officer & Senior Executive VP at Barrick Gold Corp. Mr. Shuttleworth is also on the board of Barrick TZ Ltd. In the past he occupied the position of Chief Financial Officer & Executive Director at Barrick Gold (Holdings) Ltd. Mr. Shuttleworth received an undergraduate degree from the University of Cape Town and an undergraduate degree from the University of South Africa.

Martin James Shuttleworth served as a Non-Executive Director at NuCoal Resources Ltd.
from 2002 to 2010.

Richard Peter Shuttleworth is currently the Managing Director at Brand Energy & Infrastructure Services UK Ltd.
He was previously the Chief Executive Officer & Executive Director at Redhall Group Plc from 2013 to 2014.

Stephen joined Samsara BioCapital as a Venture Partner in 2019.
He is a pharmaceutical scientist with over 25 years’ experience in the UK, US and Canada biotech industry, leading small molecule therapeutics research programs across multiple molecular targets, primarily in cancer, and also in immune-inflammation, metabolic disorders and infectious diseases.
Prior to Samsara, Stephen was CSO and Executive Director (2008-19) and joint COO/CSO/ED (2017-19) of Karus Therapeutics, UK, where he was also the founding scientist of the company’s PI3K-beta/delta and HDAC6 programs.
At Karus, he designed and directed the research and preclinical development of the two small molecule cancer therapeutics, KA2237 and KA2507, from concept to Phase I clinical trials.
Prior to Karus, he was Head of New Projects Development at Cancer Research UK in London.
Previously, Stephen was Director of Chemistry at Piramed Pharma, UK, where he directed the company’s pan-PI3K and PI3K-delta research programs, and where he designed and led the research and preclinical development of the pan-PI3K anti-cancer agent Pictilisib (PI-728/GDC-0941), which was partnered with Genentech; Piramed was subsequently acquired by Roche for $160M.
Prior to Piramed, Stephen was Associate Director, Chemistry at Tularik, South San Francisco, and, beforehand, Research Leader, Chemistry at BioChem Pharma, Quebec.
He began his industrial career at Chiroscience, UK.
He has published extensively in the literature, primarily in small molecule therapeutics R&D and in medicinal and synthetic organic chemistry, and has been an invited speaker at a number of international R&D conferences.
He is an inventor on 48 US patents, and on multiple patent applications.
Stephen received his BSc (Hons) and PhD in Chemistry from the University of Liverpool, and in 2007 was appointed a Fellow of the Royal Society of Chemistry

Mr. Stephen A.
Shuttleworth, CFA, is a Vice President & Portfolio Manager at Burgundy Asset Management Ltd.
He joined Burgundy in October 2006 to focus on accounting initiatives, and in May 2009 he assumed the role of Investment Analyst focusing on fixed income.
He transitioned to Canadian equities in June 2014 and in July 2016, he was appointed a Vice President of the firm.
As an analyst on Burgundy’s Canadian large-cap equity team, he helps identify, analyze and monitor both potential and existing portfolio companies.
He has over 10 years of combined professional experience.
He earned an Honors Bachelor of Business Administration degree (Finance) from Wilfrid Laurier University.
Mr. Shuttleworth was awarded the Chartered Financial Analyst designation in 2012.
He is also a member of CFA Institute and Toronto CFA Society.

Philip Shuttleworth has held various director positions at ECI 9 GP Ltd., ECI 10 GP Ltd., and ECI Management Ltd.
He also served as the Chief Financial Officer at ECI Partners LLP.
Mr. Shuttleworth's current job(s) include being a Director at ECI 9 GP Ltd., ECI 10 GP Ltd., and ECI Management Ltd., as well as the Chief Financial Officer at ECI Partners LLP.